Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
Conditions
Interventions
Alirocumab SAR236553 (REGN727)
Rosuvastatin
+11 more
Locations
43
United States
Excel Medical Clinical Trials, LLC-Site Number:8400001
Boca Raton, Florida, United States
Washington University School of Medicine-Site Number:8400006
St Louis, Missouri, United States
Presbyterian Novant Heart & Wellness-Site Number:8400002
Charlotte, North Carolina, United States
Cincinnati Children's Hospital Medical Center-Site Number:8400005
Cincinnati, Ohio, United States
Vanderbilt University-Site Number:8400003
Nashville, Tennessee, United States
Investigational Site Number :0320001
Buenos Aires, Argentina
Start Date
May 31, 2018
Primary Completion Date
January 14, 2021
Completion Date
August 5, 2022
Last Updated
May 6, 2023
NCT05621070
NCT06646354
NCT04507984
NCT02065180
NCT00427960
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions